Published in Vaccine Weekly, February 21st, 2007
This latest contract supports development efforts in the U.S. to evaluate the safety and effectiveness of the MF-59 adjuvant in a cell cultured based pandemic influenza vaccine. The award will also support the design, equipment and validation for a U.S.-based MF59 production facility in Holly...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly